Industry News
Biotechnology Industry News
Epicrispr Biotechnologies has used…
Epicrispr Biotechnologies has used its gene silencing tech to boost muscle mass in three patients with facioscapulohumeral muscular dystrophy, a clinical first for the debilitating disease with no approved treatments.
Biogen isn’t wasting any time…
Biogen isn’t wasting any time integrating its multibillion-dollar purchase of Apellis, revealing plans to part ways with some of the biotech’s staffers and halt work on most of its research programs.
Moderna has unveiled its first in…
Moderna has unveiled its first in vivo CAR-T program. Building on other groups’ ex vivo CAR-T data, the company plans to start clinical development of an off-the-shelf autoimmune disease prospect, dubbed “007,” next year.
EMD Serono, Merck KGaA’s North…
EMD Serono, Merck KGaA’s North American healthcare arm, has promoted from within to replace its retiring head of global commercial strategy, Andrew Paterson. Taking the commercial wheel is Miguel Fernández Alcalde, who’s spent over a
Before a biotech deal gets signed,…
Before a biotech deal gets signed, companies are already being tested by investors, pharma partners and their own pipelines. This episode looks at the pressure, timing and hard choices shaping what makes it to the
A phase 3b trial of Otsuka’s…
A phase 3b trial of Otsuka’s attention-deficit/hyperactivity disorder prospect has hit its primary endpoint, strengthening the drugmaker’s hand weeks before a potential U.S. launch of the therapy.
Ionis Pharmaceuticals has…
Ionis Pharmaceuticals has offloaded regional rights to its near-approval rare disease asset zilganersen, pocketing $30 million upfront from Recordati for an ex-U.S. license to the drug candidate.
Dr. Israel Lowy remembers the days…
Dr. Israel Lowy remembers the days when he and his oncology immunotherapy colleagues were assigned tables in the distant east wing of the American Society of Clinical Oncology conference in Chicago. They would watch aficionados
Upon finally reaching the clinic,…
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery platform it picked up in 2022.
Passage Bio, the…
Passage Bio, the Philadelphia-based gene therapy outfit that launched a strategic review earlier this year after tough feedback from the FDA, has found an exit in an all-stock reverse merger with RNA specialist Remix Therapeutics.
TechBio outfit Immunai is…
TechBio outfit Immunai is continuing its parade of Big Pharma partnerships with its third such pact this year, this time with German drugmaker Boehringer Ingelheim.
Officials are planning to study…
Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolavirus.
Amid a bustling fundraising week…
Amid a bustling fundraising week for biotechs, the U.K.’s RQ Bio is adding $115 million to its coffers to advance a long-acting antibody for flu prevention.
Novartis is paying Antares…
Novartis is paying Antares Therapeutics $105 million upfront in a deal worth up to $1.9 billion to generate small molecules against historically undruggable oncology targets.
On Tuesday afternoon at the 2026…
On Tuesday afternoon at the 2026 Biotechnology Innovation Organization conference in San Diego, Flagship Pioneering announced a research collaboration with Lean Business Services within the well-appointed Saudi Arabia pavilion in the heart of the conference’s
Half a year after toppling…
Half a year after toppling Genentech’s eye medicine giant Vabysmo in an early trial, Texas biotech Ollin Biosciences has lassoed a $330 million series B to push its winning contender through a multi-trial phase 3
An under-the-radar Bay Area…
An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch of new companies to fly its drug candidates forward.
The focus of the company is…
The focus of the company is SERP-01, an in vivo base editing program targeting AATD developed in China and licensed from YolTech Therapeutics.
Eli Lilly and Astellas have…
Eli Lilly and Astellas have emerged as “stalking horse bidders” for certain assets as part of Sangamo’s bankruptcy process.
Merck KGaA has committed $50…
Merck KGaA has committed $50 million to build a new biotech with prolific life science investor Versant Ventures, with the ultimate goal of devouring the NewCo down the line.